Stablecoin Development Corp.
Stablecoin Development Corp.
- Market cap
- $24.55M
- P/E ratio
- 0.03
Your view on SDEV
Overview
What the company does, where it operates, and who runs it.
About Stablecoin Development Corp.
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Michael Kazley
- Headquarters
- 2000 Powell Street, Emeryville, CA, US
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Michael Kazley
- Headquarters
- 2000 Powell Street, Emeryville, CA, US
Stablecoin Development Corp. specializes in manufacturing and distributing eye and skin health solutions that have undergone rigorous scientific development and proven efficacy in clinical settings. Their product portfolio features prominent brands such as Avenova, NeutroPhase, and DERMAdoctor.
This enterprise was established on January 19, 2000, and its main office is situated in Emeryville, California.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Stablecoin Development Corp.. Starting points for Stablecoin Development Corp.: P/E 0.0, EPS $2.45, beta 0.09 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Stablecoin Development Corp.. Trailing twelve-month EPS for Stablecoin Development Corp. stands at $2.45. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This quarterDec 2026 | This yearYear to Dec 2026 |
|---|---|---|
| Average estimate | $0.15 | −$1.90 |
| Lowest estimate | $0.15 | −$1.90 |
| Highest estimate | $0.15 | −$1.90 |
| Number of analysts | 1 | 1 |
| A year ago | −$4.571 | −$110.311 |
| Growth vs a year ago | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterDec 2026 | This yearYear to Dec 2026 |
|---|---|---|
| Average estimate | $5.20M | $15.80M |
| Lowest estimate | $5.20M | $15.80M |
| Highest estimate | $5.20M | $15.80M |
| Number of analysts | 1 | 1 |
| A year ago | −$521000.00 | $0.00 |
| Growth vs a year ago | +1098.1% | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Stablecoin Development Corp.. Stablecoin Development Corp. has reported as a listed company since 2007. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| EYPTEyePoint Pharmaceuticals, Inc. | Healthcare | Biotechnology | $26.6M | ||
| HROWHarrow Health, Inc. | Healthcare | Drug Manufacturers - Specialty & Generic | $1.1B | ||
| OCGNOcugen, Inc. | Healthcare | Biotechnology | $260.6M | ||
| OCSOculis Holding AG | Healthcare | Biotechnology | $435.8M | ||
| SLGLSol-Gel Technologies Ltd. | Healthcare | Biotechnology | $180.6M | ||
| TTRXTurn Therapeutics Inc. | Healthcare | Biotechnology | $247.5M | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| SDGCFSundrug Co.,Ltd. | Healthcare | OTC | $3.3B | ||
| SGIPFSugi Holdings Co.,Ltd. | Healthcare | OTC | $2.9B | ||
| SHMNSOHM, Inc. | Healthcare | OTC | $1.9M | ||
| SKVISkinvisible, Inc. | Healthcare | OTC | $1.1M | ||
| SNNCSibannac, Inc. | Healthcare | OTC | $197,600 | ||
| SPPHSpencer Pharmaceutical Inc. | Healthcare | OTC | $29,436 | ||
| SYDRFDelota Corp. | Healthcare | OTC | $2.9M | ||
| SYMQYSymBio Pharmaceuticals Limited | Healthcare | OTC | $27.2M | ||
| TNPHTian'an Pharmaceutical Co., Ltd. | Healthcare | OTC | $139,957 | ||
| TRGMTargeted Medical Pharma, Inc. | Healthcare | OTC | $3,019 | ||
| TRXBTRex Bio Inc. | Healthcare | NASDAQ | $85.9M | ||
| TSUSFTsuruha Holdings Inc. | Healthcare | OTC | $4.2B | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| VXFVanguard Extended Market ETF | $30.2B in assets | 0.00% | |
| IWCiShares Micro-Cap ETF | $1.2B in assets | 0.00% | |
Largest holders first, then the funds most concentrated in SDEV.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Stablecoin Development Corp. executives and directors. Shares of Stablecoin Development Corp. have traded between $1.00 and $2.13 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Stablecoin Development Corp.. Coverage tracks Stablecoin Development Corp. within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Stablecoin Development Corp.